Psychiatric Digital Biomarkers Market Report Scope & Overview:

The Psychiatric Digital Biomarkers Market was valued at USD 0.758 Billion in 2025 and is expected to reach USD 5.893 Billion by 2035, growing at a CAGR of 22.76% from 2026 to 2035.

The Psychiatric Digital Biomarkers market is growing at a rapid pace as this field uses artificial intelligence, machine learning, and pervasive computing in order to make advancements in the diagnosis, monitoring, and treatment of mental health disorders. This technology analyses various types of data sources including phone activity, voice and facial behavior, physical activity, and cognitive function to identify the objective presence of the disease in a patient. Neurophysiological biomarkers constitute the largest validated segment while behavioral biomarkers are showing the fastest growth owing to digital phenotyping using smartphones which is gaining popularity for non-invasive behavioral pattern detection due to high incidences of mental health disorders and the presence of government funding for research in the mental health sector.

Koneksa Health continued expanding its digital biomarker platform in 2025, advancing remote, sensor-based measurement technologies designed to support pharmaceutical clinical trials and improve the objectivity of psychiatric endpoint assessment across drug development programs.

Market Size and Forecast

• Market Size in 2026E: USD 0.931 Billion

• Market Size by 2035: USD 5.893 Billion

• CAGR: 22.76% from 2026 to 2035

• Fastest Growing Region: Europe

• Largest Region: North America

To Get more information On Psychiatric Digital Biomarkers Market- Request Free Sample Report

Psychiatric Digital Biomarkers Market Trends

• Behavioral biomarkers derived from smartphone-based digital phenotyping are demonstrating the fastest growth within the broader category.

• Pharmaceutical companies are increasingly using predictive digital biomarkers for improved clinical trial patient stratification.

• Wearable technology continues enabling real-time tracking of mental health through physiological and behavioral data.

• Growing telehealth adoption is expanding remote psychiatric monitoring capability across underserved patient populations.

• Regulatory bodies are increasingly demanding compelling clinical evidence to validate digital biomarker accuracy for clinical decision-making.

The United States Psychiatric Digital Biomarkers Market Outlook

The United States Psychiatric Digital Biomarkers Market was valued at USD 0.377 Billion in 2025 and is expected to reach USD 2.988 Billion by 2035, growing at a CAGR of 23.00% from 2026 to 2035.

North American Digital Biomarkers for Psychiatry Market - The United States was dominant in the North American Digital Biomarkers for Psychiatry market, owing to its superior digital health infrastructure, effective regulations and constant knowledge about major mental disorders that affect about 9.5% of Americans on a yearly basis. The extensive adoption of AI-based mental health solutions and investments in digital therapies further cemented the dominant standing of the country in the regional market.

Boston, MA-based Akili Interactive Labs further developed its suite of digital therapies in 2025 following previous regulatory approvals of its gaming solutions, underscoring its status as an innovator in evidence-based digital technologies designed for psychiatric disorders.

Psychiatric Digital Biomarkers Market Segmentation Analysis

• By Type, the Wearable segment held approximately 39.90% share in 2025, while the Mobile Application segment is the fastest growing.

• By Clinical Practice, the Diagnostic segment held approximately 31.20% share in 2025, while the Predictive segment is the fastest growing.

• By End Use, the Healthcare Companies segment held approximately 50.70% share in 2025, while the Healthcare Providers segment is the fastest growing.

• By Biomarker Category, the Neurophysiological segment held the largest share in 2025, while the Behavioral segment is the fastest growing.

By Type, Wearable led the market, Mobile Application grew fastest

The Wearable category was dominant among the type category in 2025 since the wearables contributed about 39.90% of the total revenue since the trend of using wearable technology has increased among the mental health treatment field. That continuous monitoring capability keeps wearable devices firmly at the top of the broader type segmentation across nearly every major psychiatric digital biomarker application.

The Mobile Application segment is projected to grow at the fastest CAGR during the forecast period, driven by increasing popularity of digital mental health tools that provide accessibility and simplicity of use alongside widespread smartphone availability. These applications offer cost-effective solutions for tracking mood, stress, and other mental health indicators, pushing this type category's growth rate ahead of the broader type segmentation for both individual and healthcare provider use cases.

By Clinical Practice, Diagnostic led the market, Predictive grew fastest

The Diagnostic segment held the largest clinical practice share in 2025, at approximately 31.20%, anchored by the urgent requirement for objective clinical assessment tools that augment subjective patient reporting in mental health evaluation. That fundamental need for quantifiable diagnostic support keeps diagnostic applications firmly at the top of the broader clinical practice segmentation across nearly every major psychiatric care setting.

The Predictive segment is projected to grow at the fastest CAGR during the forecast period, as pharmaceutical firms increasingly use predictive digital biomarkers to improve clinical trial efficiency through better patient stratification. Growing necessity for scalable remote monitoring in both patient care and drug development continues pushing this clinical practice category's growth rate ahead of the broader clinical practice segmentation.

By Biomarker Category, Neurophysiological led the market, Behavioral grew fastest

The Neurophysiological segment held the largest biomarker category share in 2025, established as the largest group to date with validation in clinical studies spanning years of accumulated research evidence. That established clinical validation record keeps neurophysiological biomarkers firmly at the top of the broader biomarker category segmentation.

The Behavioral segment is projected to grow at the fastest CAGR during the forecast period, demonstrating the highest growth via smartphone-based digital phenotyping that continues attracting interest as a non-invasive tool for behavioral pattern analysis. Rising adoption of continuous, passive behavioral data collection continues pushing this biomarker category's growth rate ahead of the broader biomarker category segmentation.

By End Use, Healthcare Companies led the market, Healthcare Providers grew fastest

The Healthcare Companies segment held the largest end-use share in 2025, at approximately 50.70%, reflecting sustained pharmaceutical and biotechnology industry investment in digital biomarker technology for drug development and clinical trial applications. That substantial industry-level investment keeps healthcare companies firmly at the top of the broader end-use segmentation across nearly every major digital biomarker deployment.

The Healthcare Providers segment is projected to grow at the fastest CAGR during the forecast period, as hospitals and clinics increasingly integrate digital biomarker tools directly into routine patient care and monitoring workflows. Rising clinical adoption of objective, technology-enabled mental health assessment continues pushing this end-use category's growth rate ahead of the broader end-use segmentation.

Regional Analysis

North America Psychiatric Digital Biomarkers Market Insights

The North American region accounted for the largest market share for the Psychiatric Digital Biomarkers Market across the globe in 2025, at about 58.40%. The growth in the prevalence of psychiatric conditions and developments in AI and wearables were among the key reasons behind this leading position along with telehealth usage. The role of strong government policies and efforts was noteworthy in 2025.

North America was also the region which made up for most of the revenue from the market, since the region contained many digital health technology manufacturers. North America comprised about 84.20% of regional revenues since the region contained all the leaders in developing digital therapeutics and had the required regulatory infrastructure.

Get Customized Report as per Your Business Requirement - Enquiry Now

Europe Psychiatric Digital Biomarkers Market Insights

Europe was the fastest-growing region in the global Psychiatric Digital Biomarkers Market, driven by the region's increasing focus on digital health transformation, government initiatives supporting mental health research, and rising adoption of wearable and AI-powered diagnostic tools. A project worth more than USD 11 million under the EU4Health program was funded to reflect the European Commission’s mental health strategy in full, which further supports the action plan of the World Health Organization on mental health.

Germany contributed nearly 27.60% towards regional revenue owing to the number of digital health technology development firms and research establishments in it. The regions of France, United Kingdom, and the Nordic countries made substantial contributions to regional demand, making Europe the undisputed market leader in terms of growth potential.

Asia Pacific Psychiatric Digital Biomarkers Market Insights

Asia Pacific held a meaningful share of the global Psychiatric Digital Biomarkers Market in 2025, supported by rising mental health awareness and growing healthcare infrastructure investment across the region's largest economies. The adoption of digital health continued to drive regional demand for the entire year.

Japan comprised around 34.10% of regional revenues due to the advanced healthcare system in place along with adoption of digital mental health technologies. China and South Korea have been contributing to a large part of regional demand due to their rapidly growing digital health ecosystem.

MEA & Latin America Psychiatric Digital Biomarkers Market Insights

The Middle East and Africa region recorded steady growth in psychiatric digital biomarkers adoption in 2025, driven by expanding digital health infrastructure investment and growing mental health awareness across the Gulf states in particular. The UAE accounted for roughly 26.30% of regional revenue, supported by national digitization strategies and rising enterprise interest in digital mental health technology.

The Latin America market also recorded a similarly robust expansion, driven primarily by Brazil, which contributed approximately 37.40% of regional revenues; the continued rise in digital healthcare usage was one of the primary factors aiding category growth. The Mexico and Argentina markets showed a similar pattern in line with rising regional mental health awareness and digital infrastructure investments.

Growth Drivers: Rising mental health prevalence and AI-enabled personalization

Mental health disorder prevalence is set to remain the dominant factor driving market growth of the psychiatric digital biomarkers market, with a significant proportion of adults suffering from depression each year in leading developed nations. Continued development in artificial intelligence and machine learning allows for increasingly accurate treatment methods, thereby facilitating market expansion in nearly all key applications.

Increasing need for personalized and remote medicine, increasing awareness about mental illnesses, and the overall trend towards less invasive and affordable diagnosis and treatment options contribute further to this growth path. Strong government support for mental health research and innovation, combined with expanding pharmaceutical industry adoption for clinical trial applications, keeps demand growth firmly intact across nearly every major psychiatric digital biomarker category worldwide.

Restraints: Clinical validation challenges and regulatory uncertainty

Proving clinical validity and usefulness for digital biomarkers in psychiatric applications remains the greatest challenge confronting the market, as digital biomarkers depend on sophisticated algorithmic interpretations of physiological and behavioral data subject to many confounding variables. Unlike conventional biomarkers with well-defined biochemical correlates, digital biomarkers require considerably more complex validation methodologies.

Regulatory bodies continue demanding compelling clinical evidence that digital biomarkers can accurately detect, monitor, or forecast psychiatric disorders with the precision required for clinical decision-making. That validation and regulatory hurdle continues requiring specialized expertise and extended development timelines that can meaningfully slow market entry for smaller technology developers.

Opportunities: Underserved region access and pharmaceutical trial efficiency gains

Expanding access to scalable, continuous, affordable psychiatric health monitoring tools in underserved regions presents substantial opportunity for technology developers positioned to serve populations historically lacking access to specialized mental health assessment. Companies capable of delivering genuinely accessible, low-cost digital biomarker platforms stand to capture a growing share of demand across emerging healthcare markets.

Companies that enhance trial efficiency through the use of predictive biomarkers for effective patient stratification represent another important source of future growth potential, as the convergence of technology and healthcare keeps enabling intelligent platforms that can provide personalized psychiatric treatment. Technology companies that can prove clinical trial efficiency will benefit from new sources of income until 2035.

Recent Developments:

• 2025: Biogen continued expanding its digital biomarker research collaborations, advancing sensor-based measurement technologies designed to support neuropsychiatric drug development and clinical trial endpoint assessment.

• 2025: Empatica continued advancing its wearable physiological monitoring platform, strengthening its position supporting continuous, real-time mental health data collection for both clinical research and patient care applications.

• 2024: Sonde Health continued expanding its voice-based mental health screening technology, targeting healthcare provider and payer customers seeking objective, non-invasive tools for depression and anxiety assessment.

Psychiatric Digital Biomarkers Market key players are:

• Koneksa Health Inc.

• Biogen Inc.

• BioSensics LLC

• Empatica Inc.

• VivoSense Inc.

• IXICO plc

• Huma Therapeutics Ltd.

• Kintsugi Health, Inc.

• Sonde Health, Inc.

• Clario

• icometrix NV

• iMediSync Inc.

• Woebot Health, Inc.

• Neurotrack Technologies, Inc.

• Quartet Health, Inc.

• Linus Health, Inc.

• Akili Interactive Labs, Inc.

• Verily Life Sciences LLC

• Mindstrong Health, Inc.

• Winterlight Labs Inc.

Psychiatric Digital Biomarkers Market Report Scope :